Chronic Myeloid Leukemia – Current Treatment – Detailed, Expanded Analysis: Treatment Sequencing (US)

Key benefits and uses

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting
  • Drill down into physicians’ treatment sequences and understand whom to position against or how to defend share
  • Identify untapped treatment scenarios and key competitors to aid trial design
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages
  • Discover untapped populations to expand product share and drive strategic decisions

Questions answered

  • Where is my product positioned versus competitors in the treatment journey?
  • What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios according to oncology experts?
  • Where are the untapped business opportunities on which I can capitalize?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?


United States

Primary market research

Survey of 103 U.S. hematologist-oncologists

Product description

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts’ assumptions.

launch Related Market Assessment Reports